Patient demographics and disease characteristics during chronic-phase MPN and at diagnosis of MPN-AP/BP
| Demographics . | N = 202 . |
|---|---|
| Age (y) at chronic-phase MPN diagnosis, median (range) | 61.9 (21.9-91.0) |
| Female, n (%) | 80 (39.6) |
| Race/ethnicity, n (%) | n = 158 |
| White | 142 (89.9) |
| Black | 9 (5.7) |
| Asian | 3 (1.9) |
| Other | 4 (2.5) |
| Hispanic ethnicity | 11 (7.0) |
| Chronic-phase MPN | N = 202 |
| Polycythemia vera | 40 (20%) |
| Essential thrombocythemia | 57 (28%) |
| Primary myelofibrosis | 67 (33%) |
| MPN-not otherwise specified/other | 38 (19%) |
| Driver mutation | N = 202 |
| JAK2 | 124 (61%) |
| CALR | 33 (16%) |
| MPL | 18 (9%) |
| Triple-negative | 27 (13%) |
| Therapies received for chronic-phase MPN | N = 202 |
| Hydroxyurea | 124 (61%) |
| JAK inhibitor | 72 (36%) |
| Interferon | 7 (4%) |
| DNMTi | 11 (5%) |
| Other | 39 (19%) |
| Allo-HSCT | 6 (3%) |
| MPN-AP/BP characteristics | N = 202 |
| Age at accelerated/blast phase MPN, median (range) | 68.6 (22.7-94.0) |
| Latency period in years between chronic-phase MPN and MPN-AP/BP, median (range) | 4.5 (0.0-44.2) |
| WBC (103/μL), median (range) | 9.8 (0.6-144.6) |
| Hemoglobin (g/dL), median (range) | 8.6 (5.1-16.5) |
| Platelets (103/μL), median (range) | 99.0 (4.0-1839.0) |
| Peripheral blast %, median (range) | 13.0 (0.0-91.0) |
| Marrow blast %, median (range) | 22.0 (0.0-97.0) |
| Creatinine (g/dL), median (range) | 0.95 (0.5-7.0) |
| Total bilirubin (g/dL), median (range) | 0.7 (0.2-3.4) |
| Palpable splenomegaly, n (%) | 102 (52.0) |
| 2017 ELN risk at MPN-AP/BP diagnosis | n = 189 |
| Favorable | 5 (2.6) |
| Intermediate | 58 (30.7) |
| High risk | 126 (66.7) |
| Mutations at MPN-AP/BP diagnosis | n = 166 |
| ASXL1 | 52 (31%) |
| TP53 | 43 (26%) |
| SRSF2 | 39 (23%) |
| IDH2 | 24 (14%) |
| EZH2 | 15 (9%) |
| U2AF1 | 12 7%) |
| IDH1 | 11 (7%) |
| Demographics . | N = 202 . |
|---|---|
| Age (y) at chronic-phase MPN diagnosis, median (range) | 61.9 (21.9-91.0) |
| Female, n (%) | 80 (39.6) |
| Race/ethnicity, n (%) | n = 158 |
| White | 142 (89.9) |
| Black | 9 (5.7) |
| Asian | 3 (1.9) |
| Other | 4 (2.5) |
| Hispanic ethnicity | 11 (7.0) |
| Chronic-phase MPN | N = 202 |
| Polycythemia vera | 40 (20%) |
| Essential thrombocythemia | 57 (28%) |
| Primary myelofibrosis | 67 (33%) |
| MPN-not otherwise specified/other | 38 (19%) |
| Driver mutation | N = 202 |
| JAK2 | 124 (61%) |
| CALR | 33 (16%) |
| MPL | 18 (9%) |
| Triple-negative | 27 (13%) |
| Therapies received for chronic-phase MPN | N = 202 |
| Hydroxyurea | 124 (61%) |
| JAK inhibitor | 72 (36%) |
| Interferon | 7 (4%) |
| DNMTi | 11 (5%) |
| Other | 39 (19%) |
| Allo-HSCT | 6 (3%) |
| MPN-AP/BP characteristics | N = 202 |
| Age at accelerated/blast phase MPN, median (range) | 68.6 (22.7-94.0) |
| Latency period in years between chronic-phase MPN and MPN-AP/BP, median (range) | 4.5 (0.0-44.2) |
| WBC (103/μL), median (range) | 9.8 (0.6-144.6) |
| Hemoglobin (g/dL), median (range) | 8.6 (5.1-16.5) |
| Platelets (103/μL), median (range) | 99.0 (4.0-1839.0) |
| Peripheral blast %, median (range) | 13.0 (0.0-91.0) |
| Marrow blast %, median (range) | 22.0 (0.0-97.0) |
| Creatinine (g/dL), median (range) | 0.95 (0.5-7.0) |
| Total bilirubin (g/dL), median (range) | 0.7 (0.2-3.4) |
| Palpable splenomegaly, n (%) | 102 (52.0) |
| 2017 ELN risk at MPN-AP/BP diagnosis | n = 189 |
| Favorable | 5 (2.6) |
| Intermediate | 58 (30.7) |
| High risk | 126 (66.7) |
| Mutations at MPN-AP/BP diagnosis | n = 166 |
| ASXL1 | 52 (31%) |
| TP53 | 43 (26%) |
| SRSF2 | 39 (23%) |
| IDH2 | 24 (14%) |
| EZH2 | 15 (9%) |
| U2AF1 | 12 7%) |
| IDH1 | 11 (7%) |